Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero Murillo, Mercedes
  • Marchese, Domenica, 1986-
  • Heyn, Holger
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero-Murillo, Mercedes
  • Rill-Hinarejos, Aina
  • Trincado, Juan L.
  • Bataller, Alex
  • Ortiz-Maldonado, Valentín
  • Benítez-Ribas, Daniel
  • Español-Rego, Marta
  • González-Navarro, Azucena
  • Martínez-Cibrián, Nuria
  • Marchese, Domenica
  • Martín-Martín, Lourdes
  • García-Sancho, Alejandro Martín
  • Rives, Susana
  • Heyn, Holger
  • Juan, Manel
  • Urbano-Ispizúa, Álvaro
  • Delgado, Julio
  • Orfao, Alberto
  • Mereu, Elisabetta
  • Bueno, Clara
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML

  • Bousquets-Muñoz, Pablo
  • Molina, Oscar
  • Varela, Ignacio
  • Álvarez-Eguiluz, Ángel
  • Gómez Peris, Ana
  • Sánchez, Elena G.
  • Balbín, Milagros
  • Ruano, David
  • Ramírez-Orellana, Manuel
  • Puente, Xose S.
  • Menéndez, Pablo
Acute leukemia is the most frequently diagnosed malignancy in childhood, with acute lymphoblastic leukemia (ALL) comprising approximately 80% of cases in children aged 0–18 years, and acute myeloid leukemia (AML) accounting for approximately 15–20% [1]. The early onset (0–10 years) of most childhood acute leukemias and the high concordance rate among monozygotic twins suggest a prenatal origin of the disease [1]. Indeed, the presence of preleukemic precursors in cord blood (CB) samples or Guthrie blood spots from children who later developed acute leukemia has been demonstrated in several studies [2, 3]. However, this has mainly been demonstrated experimentally for the most common cytogenetic subtypes, particularly in ALL., This research was partially supported by a donation from the patient’s family and Heroga Fertilizantes. Research in PM’s laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), the H2020 EU program (101057250-CANCERNA), the MINECO (PID2022-142966OB-I00/ MCIN/AEI/10.13039/501100011033 and Feder Funds), the MINECO/European Union NextGenerationEU (CPP2021-008508, CPP2022-009759); the Deutsche José Carreras Leukämie-Stiftung (DJCLS15R/2021 and DJCLS 02R/2023), the Spanish Association Against Cancer (AECC, PRYGN234975MENE) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Research in XSP’s laboratory is supported by Ministerio de Ciencia e Innovación (PID2020-117185RB-I00); the Spanish Association Against Cancer (AECC); Centro de Investigación Biomédica en Red Cáncer (CIBERONC); “La Caixa” Foundation CLLSYSTEMS (HR22-00172), European Union NextGenerationEU/Mecanismo para la Recuperación y la Resilencia (MRR)/PRTR and the Instituto de Salud Carlos III (ISCIII) (PMP21/00015). OM and TV-H were supported by an investigator award from AECC (INVES211226MOLI and INVES223069VELA, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

  • Arroyo-Ródenas, Javier
  • Falgàs, Aïda
  • Díez-Alonso, Laura
  • Martínez-Moreno, Alba
  • Roca-Ho, Heleia
  • Gil-Etayo, Francisco J.
  • Pérez-Pons, Alba
  • Aguilar-Sopeña, Óscar
  • Velasco-Sidro, Miriam
  • Gómez-Rosel, Marina
  • Jiménez-Matías, Beatriz
  • Muñoz-Sánchez, Guillermo
  • Pacheco, Yedra
  • Bravo-Martín, Clara
  • Ramírez-Fernández, Ángel
  • Jiménez-Reinoso, Anaïs
  • González-Navarro, Azucena
  • Juan, Manel
  • Orfao, Alberto
  • Blanco, Belén
  • Roda-Navarro, Pedro
  • Bueno, Clara
  • Menéndez, Pablo
  • Álvarez-Vallina, Luis
[Background] CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically., [Methods] We have generated the first dual-targeting strategy for B-cell malignancies based on CD22 CAR-T cells secreting an anti-CD19 TCE antibody (CAR-STAb-T) and conducted a comprehensive preclinical characterization comparing its therapeutic potential in B-ALL with that of previously validated dual-targeting CD19/CD22 tandem CAR cells (TanCAR-T cells) and co-administration of two single-targeting CD19 and CD22 CAR-T cells (pooled CAR-T cells)., [Results] We demonstrate that CAR-STAb-T cells efficiently redirect bystander T cells, resulting in higher cytotoxicity of B-ALL cells than dual-targeting CAR-T cells at limiting effector:target ratios. Furthermore, when antigen loss was replicated in a heterogeneous B-ALL cell model, CAR-STAb T cells induced more potent and effective cytotoxic responses than dual-targeting CAR-T cells in both short- and long-term co-culture assays, reducing the risk of CD19-positive leukemia escape. In vivo, CAR-STAb-T cells also controlled leukemia progression more efficiently than dual-targeting CAR-T cells in patient-derived xenograft mouse models under T cell-limiting conditions., [Conclusions] CD22 CAR-T cells secreting CD19 T-cell engagers show an enhanced control of B-ALL progression compared with CD19/CD22 dual CAR-based therapies, supporting their potential for clinical testing., Research in LA-V laboratory is funded by the MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021-121711-I00, CPP2022-009762, CPP2022-009765, CPP2023-010827), the Carlos III (ISCIII) Health Institute with European Regional Development Fund (FEDER) cofinancing (DTS20/00089, PMPTA22/00167); the Asociación Española contra el Cáncer (AECC) (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS-2021-0090 and FCRIS-2023-0070), the Fundación ‘‘La Caixa’’ (HR21-00761 project IL7R_LungCan), the Fundación para la Investigación Biomédica del Hospital 12 de Octubre (programa Investiga 2022-0082), the Comunidad de Madrid (P2022/BMD-7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). Research in PM/CB laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support; “the European Research Council grants (ERC-PoC-957466 IT4B-TALL, ERC-PoC-101100665 BiTE-CAR); H2020 (101057250-CANCERNA), the MCIN/AEI/10.13039/501100011033 (PID2022-142966OB-I00 and Feder Funds), MCIN/European Union NextGeneration EU (CPP2021-008508 and CPP2022-009759); the AECC (PRYGN234975MENE and PRYGN211192BUEN), the Fundación Unoentrecienmil (FUECM2024), the ISCIII/FEDER (PI20/00822, PI24/00763) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). BB is supported by the ISCIII (PI23/01256), AECC (INNOV211832BLAN) and Comunidad de Madrid (IND2022/BMD-23732). PR-N is funded by MCIN/AEI/10.13039/501100011033 (PID2020-115444GB-I00). AF was supported by a Juan de la Cierva fellowship from the Ministerio de Ciencia, Innovación y Universidades. LDA was supported by a Rio Hortega fellowship from the ISCIII (CM20/00004). OA-S was supported by a PhD fellowship from the Complutense University of Madrid. MG-R is supported by an Industrial PhD fellowship from Comunidad de Madrid (IND2022/BMD-23732)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero Murillo, Mercedes
  • Marchese, Domenica, 1986-
  • Heyn, Holger
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).